Arginase deficiency is a rare autosomal recessive metabolic disorder that disrupts the final step of the urea cycle, impairing the conversion of arginine into urea and ornithine. In affected ...
What determines whether astrocytes play a beneficial or detrimental role in Alzheimer’s disease? It’s surely complicated, but a study in the June 10 online Cell Metabolism lays some of the blame on ...
The number of elderly suffering from Alzheimer’s Disease has been rapidly rising over the past decades. For a long time, scientists believed that misfolded aggregates of amyloid-beta protein ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) in partnership with Invitae Corporation (NYSE: NVTA) today announced a new urea cycle disorder (UCD) genetic testing program designed ...
A physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the United States. An Indiana University School of Medicine ...
An Indiana University School of Medicine physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the United States. By ...
Targeted inhibition of an enzyme linked to the urea cycle called ornithine decarboxylase 1 (ODC1) in star-shaped cells in the brain called astrocytes, could prove beneficial in restoring memory ...
PASADENA, Calif. and CELEBRATION, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- The National Urea Cycle Disorders Foundation (NUCDF) and Zevra Therapeutics, Inc. (ZVRA) are teaming up to launch an awareness ...
Boehringer Ingelheim will be commencing a new collaboration with Thoeris GmbH with the goal of advancing a first-in-class approach for the treatment of urea cycle disorders (UCDs) independent of the ...
An Indiana University School of Medicine physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the United States. By ...
The application was approved through the FDA’s 505(b)(2) regulatory pathway. The Food and Drug Administration (FDA) has approved Olpruva ™ (sodium phenylbutyrate) as an oral suspension for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results